Verrica Slides After FDA Approval of Ycanth for Molluscum (1)

Verrica Pharmaceuticals Inc. says the US FDA approved topical solution Ycanth to treat molluscum contagiosum in adult and pediatric patients 2 years of age and older. The stock fell as much as 16% in postmarket trading.

• Co. plans to make Ycanth available by September 2023

To view the source of this information, click here

(Adds shares in first paragraph.)

--With assistance from Jeran Wittenstein.

To contact the reporter on this story:
Cara Moffat in Los Angeles at cmoffat@bloomberg.net

To contact the editors responsible for this story:
Sunil Kesur at skesur@bloomberg.net

Dawn McCarty

© 2023 Bloomberg L.P. All rights reserved. ...